Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Advertisement

Advertisement

Advertisement

Recent News

News
Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML
10/31/2024
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy...
10/31/2024
Oncology
News
Safety of Encorafenib Plus Binimetinib and Pembrolizumab for Advanced BRAF V600-Mutant Melanoma
10/31/2024
A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.
A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.
A safety lead-in for the...
10/31/2024
Oncology
News
Novel Next-Generation Sequencing Assay Proves Accurate in Detecting Mutations Among Patients Advanced HR-Positive, HER2-Negative Breast Cancer
10/31/2024
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS...
10/31/2024
Oncology
News
Fedratinib Demonstrates Promising Efficacy for Second-Line Treatment of Myelofibrosis
10/31/2024
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial,...
10/31/2024
Oncology
News
Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients With HR-Positive, HER2-Negative Breast Cancer
10/29/2024
Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Primary results from the...
10/29/2024
Oncology
FDA Approval
FDA Grants Accelerated Approval to Frontline Asciminib for Patients With Ph+ Chronic Myeloid Leukemia
10/29/2024
The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
The FDA granted accelerated approval to asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
The FDA granted accelerated...
10/29/2024
Oncology
News
Ramucirumab Added to Osimertinib Prolongs PFS for Patients With TKI-Naïve EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
10/29/2024
Results from the phase 2 RAMOSE study demonstrated that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival for patients with TKI-naive EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 2 RAMOSE study demonstrated that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival for patients with TKI-naive EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 2 RAMOSE...
10/29/2024
Oncology
News
Perioperative Chemoimmunotherapy Show Long-Term Benefit for Patients With Resectable Stage IIIA Non-Small Cell Lung Cancer
10/29/2024
According to updated 5-year results from the phase 2 NADIM trial, perioperative chemotherapy plus nivolumab sustains clinical benefit for patients with resectable stage IIIA non-small cell lung cancer.
According to updated 5-year results from the phase 2 NADIM trial, perioperative chemotherapy plus nivolumab sustains clinical benefit for patients with resectable stage IIIA non-small cell lung cancer.
According to updated 5-year...
10/29/2024
Oncology
News
Adjuvant Pembrolizumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma
10/24/2024
According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.
According to the phase 3 AMBASSADOR trial, adjuvant pembrolizumab significantly improved disease-free survival among patients with high-risk muscle-invasive urothelial carcinoma.
According to the phase 3...
10/24/2024
Oncology
News
Perioperative Durvalumab Improved Survival Outcomes for Patients With Operable, Muscle-Invasive Bladder Cancer
10/24/2024
According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...
According to the phase 3 NIAGARA trial, the addition of perioperative durvalumab to neoadjuvant chemotherapy significantly improved event-free survival and overall survival among cisplatin-eligible patients with operable, muscle-invasive...
According to the phase 3 NIAGARA...
10/24/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement